Science and Research

A Randomized, double-blind, placebo-controlled, Phase 1b, dose escalation, safety, tolerability and pharmacodynamic biomarker study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in recently diagnosed, treatment naïve subjects with Idiopathic Pulmonary Fibrosis

This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.

Study details
Study-ID: NCT05954988
Study-ID: NCT05954988
DZL Disease Area: DPLD
DZL Disease Area: DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: UGMLC
DZL Participating Sites: UGMLC
Start Date: 06.07.2023
Completion Date: 25.09.2024
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.